Current market catalysts

Nuwellis Says Financial Efficiency Strategy Drove Q2 2026 Gross Margin To 76% From 56%; Says It Had About $8.8M In Cash As Of August 31, With Runway Into Q3 2027

Aspire-Lakewood Holdings Announces $10M Stock Repurchase Program

This expanded share repurchase program is effective September 9, 2026. The expanded authorization reflects the Company's continued confidence in its long-term strategy as a holding company and strong free cash flow

IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day

IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the

Intelligent Bio Submits Comprehensive Clinical Data to Enter US Drug Screening Market

Intelligent Bio Solutions submitted a 510(k) notification to the FDA for its fingerprint drug screening system to enter the US market.

8-K filing — bioAffinity Technologies, Inc. (BIAFW)

Filed: 2026-09-09 AccNo: 0001493152-26-041894 Size: 308 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — electroCore, Inc. (ECOR)

Filed: 2026-09-09 AccNo: 0001493152-26-041893 Size: 764 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — Definitive Healthcare Corp. (DH)

Filed: 2026-09-09 AccNo: 0001193125-26-385950 Size: 160 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Stephens & Co. Maintains Overweight on Braze, Raises Price Target to $34

Stephens & Co. analyst Brett Huff maintains Braze (NASDAQ:BRZE) with a Overweight and raises the price target from $31 to $34.

Coinbase’s Kalshi Push Gets New Backbone With ION’s Real-Time Trading Tech

Coinbase adopts ION’s XTP to scale its Kalshi prediction market ops, boosting COIN premarket stock 1% despite broader market declines.

Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73

Freedom Capital Markets analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $73.

Takeda's Phase 3 Trial Of Oveporexton's Data Published In New England Journal Of Medicine To Treat Narcolepsy Type 1; Oveporexton Generally Well-Tolerated With Consistent Safety Profile

Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with

Needham Reiterates Buy on Braze, Maintains $50 Price Target

Needham analyst Scott Berg reiterates Braze (NASDAQ:BRZE) with a Buy and maintains $50 price target.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: New Issue Available

Freedom Capital Markets Maintains Buy on ABM Indus, Raises Price Target to $58

Freedom Capital Markets analyst David Silver maintains ABM Indus (NYSE:ABM) with a Buy and raises the price target from $55 to $58.

8-K filing — Alcoa Corp (AA)

Filed: 2026-09-09 AccNo: 0001193125-26-385947 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — GameSquare Holdings, Inc. (GAME)

Filed: 2026-09-09 AccNo: 0001493152-26-041889 Size: 204 KB Item 8.01: Other Events

Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target

Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.

Canaccord Genuity Maintains Buy on Chime Financial, Raises Price Target to $50

Canaccord Genuity analyst Joseph Vafi maintains Chime Financial (NASDAQ:CHYM) with a Buy and raises the price target from $45 to $50.

Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $13.

8-K filing — ANALOG DEVICES INC (ADI)

Filed: 2026-09-09 AccNo: 0001193125-26-385938 Size: 164 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — GameSquare Holdings, Inc. (GAME)

Filed: 2026-09-09 AccNo: 0001493152-26-041884 Size: 874 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

Stratasys Launches Its F870 FDM System Large-Format Additive Manufacturing Platform At Toyota And Rivian Factories In The U.S.

Extending the Stratasys production-grade FDM portfolio, the F870 combines unrivaled large-format capabilities in a heated chamber backed by a suite of the strongest, most durable materials, all with a lower total cost

Ocean Power Technologies To Take Part Uncrewed Surface Vehicle Demonstration In U.S. Army Engineer Research And Development Center's Coastal And Hydraulics Lab

Ocean Power Technologies, Inc. ("OPT" or the "Company") (NYSE:OPTT), a leader in intelligent maritime solutions and services, today announced that it is participating in a week-long uncrewed surface

Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and maintains $123 price target.

ADP Employment Change Weekly 12.00K Vs 11.80K Prior

This AI Chipmaker Looks Like a Bargain With AI Revenue Set to Double Again Next Year

Broadcom, a leading ASIC chip designer, expects its AI semiconductor revenue to double in fiscal 2027 and double again in fiscal 2028. Despite impressive business fundamentals with 48% overall revenue growth and 88% net income growth in Q2 2026, the stock has underperformed the S&P 500, trading at a low 19x forward P/E ratio that doesn't reflect its strong growth prospects.

I'm Not Worried About a Bear Market in 2026. Here's Why.

The author argues that long-term investors shouldn't fear bear markets, as they present buying opportunities through dollar-cost averaging. Using the Vanguard Morningstar Total Stock Market ETF as an example, the article demonstrates that even investing before the 2022 bear market would have yielded positive returns today. The key strategy is to maintain a diversified portfolio and stick to an investment plan rather than attempting to time the market.

Bakkt Expands Global Commercial Team as Growth Accelerates; Raises 2026 Total Transacting Volume Target to $3 Billion

Bakkt announced a significant expansion of its global commercial organization with new senior executive appointments across institutional partnerships, markets, and U.S. sales. The company raised its full-year 2026 Total Transacting Volume target from $2.5 billion to $3 billion, citing strengthened commercial organization and customer demand exceeding initial assumptions. Bakkt is developing sector-specific product suites for commodity industries and expects these initiatives to materially increase transaction volumes in 2027.

Centrus Energy Trending After Signing Multi-Year Uranium Deal With Radiant

Centrus Energy is trending after the company announced a multi-year contract to supply HALEU for Radiant's Kaleidos microreactor fleet.

Jersey Mike’s First Post-IPO Earnings: CEO Says Traffic Is Accelerating Despite Industrywide Weakness

Jersey Mike's stock rises after Q2 earnings show strong traffic, $208M revenue, and higher adjusted EBITDA.